SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will jointly present with Roche at the SCRIP conference, "Developing and Managing Strategic Alliances," to be held in Berlin, Germany on May 15 and 16, 2007.
Eric de La Fortelle, Global head of External Research and Technologies at Roche, and Robert J. Little, Vice President, Chief Commercial Officer at Halozyme, will jointly present an overview of each company, including an outline of Halozyme's Enhanze(TM) Technology. The executives will describe the rationale behind Roche licensing the technology for use with its biologics compounds, the rapid and flexible process for establishing the alliance and the efforts to make the alliance operational in a timely and efficient manner.
Interested parties can access the presentation via the Internet by visiting the Investor Relations section of the Company's Web site at www.halozyme.com.
About Enhanze Technology
Enhanze Technology is Halozyme's proprietary drug delivery technology based on recombinant human hyaluronidase (rHuPH20), a recombinant form of the naturally occurring human enzyme approved by FDA for its ability to break down hyaluronic acid (HA), the space-filling "gel"-like substance that is a major component of tissues throughout the body. When combined or co-formulated with certain injectable drugs, Enhanze Technology can act as a "molecular machete" to facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin. Molecules as large as 200 nanometers may pass freely through the perforated extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for 13 targets. In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the content of the presentation) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Halozyme Contact Investor Relations Contact David A. Ramsay Don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100 dramsay@halozyme.comdmarkley@lhai.com Media Contacts Karen Sparks / Joleen Schultz Mentus (858) 455-5500, x275/x215 karen@mentus.comjschultz@mentus.com
Halozyme Therapeutics, Inc.CONTACT: David A. Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8881, dramsay@halozyme.com; or InvestorRelations, Don Markley of Lippert/Heilshorn & Associates, +1-310-691-7100,dmarkley@lhai.com, for Halozyme Therapeutics, Inc.; or Media, Karen Sparks,ext. 275, karen@mentus.com, or Joleen Schultz, ext. 215,jschultz@mentus.com, both of Mentus, +1-858-455-5500, for HalozymeTherapeutics, Inc.
Web site: http://www.halozyme.com/
